erlotinib hydrochloride has been researched along with capsanthin in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (capsanthin) | Trials (capsanthin) | Recent Studies (post-2010) (capsanthin) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 72 | 1 | 45 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chien, YC; Huang, WC; Hung, CC; Liu, LC; Tsai, IC; Wu, JY; Yu, YL | 1 |
1 other study(ies) available for erlotinib hydrochloride and capsanthin
| Article | Year |
|---|---|
Capsanthin induces G1/S phase arrest, erlotinib-sensitivity and inhibits tumor progression by suppressing EZH2-mediated epigenetically silencing of p21 in triple-negative breast cancer cells.
Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Epigenesis, Genetic; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Mice; Triple Negative Breast Neoplasms; Xanthophylls | 2021 |